Ideaya Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update

 

• 75% eye preservation rate (9 of 12 enucleation patients)
• ~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median tumor shrinkage of 47% by volume change after 6 months
• Company-sponsored Phase 2 Neoadjuvant UM: Over 40 patients enrolled, and for the 8 patients with ≥4-months of darovasertib observed median tumor shrinkage of 72% by volume change and eye preserved for the majority of enucleation patients
• Targeting Type C meeting with the FDA in H2 2024 for guidance on potential registrational trial for darovasertib in neoadjuvant UM setting
• Projected global annual incidence of primary UM is ~8,000 to ~10,000 patients

https://www.biospace.com/article/releases/ideaya-announces-results-for-darovasertib-phase-2-ist-in-neoadjuvant-uveal-melanoma-at-asco-and-clinical-update-for-phase-2-company-sponsored-neoadjuvant-study/